Want to see ZVRA full AI Analyst Report?
Zevra Therapeutics (ZVRA) Ratios
Zevra Therapeutics Ratios
ZVRA's free cash flow for Q2 2026 was $16.82M. For the 2026 fiscal year, ZVRA's free cash flow was decreased by $-217.00K and operating cash flow was $17.03M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.68 | 2.53 | 1.18 | 7.72 | 27.20 |
| Quick Ratio | 5.63 | 2.47 | 0.85 | 7.72 | 27.20 |
| Cash Ratio | 1.59 | 0.99 | 0.58 | 5.45 | 26.56 |
| Solvency Ratio | 0.67 | -0.72 | -0.41 | -0.64 | -1.43 |
| Operating Cash Flow Ratio | -0.04 | -2.05 | -0.45 | -1.56 | 2.47 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -0.89 | -4.02 | 0.00 |
| Net Current Asset Value | $ 92.93M | $ -52.43M | $ -23.52M | $ 52.61M | $ 109.23M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.34 | 0.25 | 0.16 | 0.01 |
| Debt-to-Equity Ratio | 0.41 | 1.52 | 0.71 | 0.25 | 0.01 |
| Debt-to-Capital Ratio | 0.29 | 0.60 | 0.41 | 0.20 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.29 | 0.60 | 0.08 | 0.15 | 0.00 |
| Financial Leverage Ratio | 1.84 | 4.49 | 2.79 | 1.54 | 1.05 |
| Debt Service Coverage Ratio | 11.94 | -12.48 | -1.11 | -5.11 | -21.07 |
| Interest Coverage Ratio | -0.53 | -11.84 | -33.05 | -127.06 | 20.56 |
| Debt to Market Cap | 0.12 | 0.15 | 0.18 | 0.11 | 0.00 |
| Interest Debt Per Share | 1.29 | 1.46 | 1.28 | 0.55 | 0.07 |
| Net Debt to EBITDA | 0.01 | -0.35 | -0.02 | 1.83 | 14.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 84.52% | 68.59% | 89.28% | 97.82% | 92.81% |
| EBIT Margin | 88.90% | -350.62% | -162.22% | -260.51% | -28.43% |
| EBITDA Margin | 92.71% | -323.56% | -158.56% | -251.22% | -27.53% |
| Operating Profit Margin | -3.98% | -368.47% | -180.63% | -418.91% | 26.98% |
| Pretax Profit Margin | 81.41% | -381.76% | -167.69% | -263.80% | -29.74% |
| Net Profit Margin | 78.17% | -446.85% | -167.69% | -263.48% | -29.86% |
| Continuous Operations Profit Margin | 78.17% | -446.85% | -167.69% | -263.48% | -29.86% |
| Net Income Per EBT | 96.02% | 117.05% | 100.00% | 99.88% | 100.40% |
| EBT Per EBIT | -2047.67% | 103.61% | 92.83% | 62.97% | -110.25% |
| Return on Assets (ROA) | 29.23% | -59.23% | -26.72% | -23.21% | -6.44% |
| Return on Equity (ROE) | 53.82% | -266.00% | -74.44% | -35.64% | -6.73% |
| Return on Capital Employed (ROCE) | -1.72% | -60.39% | -50.30% | -41.20% | 6.00% |
| Return on Invested Capital (ROIC) | -1.65% | -60.22% | -36.25% | -39.20% | 5.99% |
| Return on Tangible Assets | 30.42% | -101.03% | -46.80% | -23.21% | -6.44% |
| Earnings Yield | 16.79% | -27.35% | -19.83% | -16.91% | -3.30% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.58 | 2.25 | 1.58 | 1.22 | 18.75 |
| Payables Turnover | 6.65 | 0.57 | 0.21 | 0.06 | 3.99 |
| Inventory Turnover | 9.47 | 3.76 | 0.12 | 0.00 | 0.00 |
| Fixed Asset Turnover | 62.59 | 23.31 | 18.00 | 5.70 | 14.15 |
| Asset Turnover | 0.37 | 0.13 | 0.16 | 0.09 | 0.22 |
| Working Capital Turnover Ratio | 0.90 | 0.72 | 0.58 | 0.11 | 0.51 |
| Cash Conversion Cycle | 63.39 | -384.04 | 1482.13 | -5638.89 | -72.00 |
| Days of Sales Outstanding | 79.73 | 162.45 | 230.97 | 298.11 | 19.47 |
| Days of Inventory Outstanding | 38.53 | 96.95 | 2984.70 | 0.00 | 0.00 |
| Days of Payables Outstanding | 54.88 | 643.44 | 1733.53 | 5937.00 | 91.47 |
| Operating Cycle | 118.27 | 259.40 | 3215.66 | 298.11 | 19.47 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.03 | -1.51 | -0.95 | -0.54 | 0.35 |
| Free Cash Flow Per Share | -0.04 | -1.51 | -0.95 | -0.55 | 0.35 |
| Dividend Paid and CapEx Coverage Ratio | -1.91 | 0.00 | -113.29 | -201.26 | 102.34 |
| Capital Expenditure Coverage Ratio | -1.91 | 0.00 | -113.29 | -201.26 | 102.34 |
| Operating Cash Flow Coverage Ratio | -0.03 | -1.16 | -0.77 | -1.00 | 6.49 |
| Operating Cash Flow to Sales Ratio | -0.02 | -2.95 | -1.22 | -1.84 | 0.36 |
| Free Cash Flow Yield | -0.49% | -18.06% | -14.57% | -11.88% | 3.99% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 6.40 | -3.66 | -5.04 | -5.91 | -30.31 |
| Price-to-Sales (P/S) Ratio | 4.65 | 16.34 | 8.46 | 15.58 | 9.05 |
| Price-to-Book (P/B) Ratio | 3.20 | 9.72 | 3.75 | 2.11 | 2.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -203.69 | -5.54 | -6.86 | -8.42 | 25.08 |
| Price-to-Operating Cash Flow Ratio | -310.13 | -5.54 | -6.92 | -8.46 | 24.84 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | -0.05 | -0.08 | 0.09 | 0.88 |
| Enterprise Value Multiple | 5.03 | -5.40 | -5.35 | -4.37 | -18.83 |
| Enterprise Value | 496.39M | 412.25M | 232.93M | 111.62M | 148.53M |
| EV to EBITDA | 5.03 | -5.40 | -5.35 | -4.37 | -18.83 |
| EV to Sales | 4.66 | 17.46 | 8.48 | 10.98 | 5.18 |
| EV to Free Cash Flow | -204.02 | -5.92 | -6.89 | -5.93 | 14.37 |
| EV to Operating Cash Flow | -310.63 | -5.92 | -6.95 | -5.96 | 14.23 |
| Tangible Book Value Per Share | 2.60 | -0.74 | -0.34 | 2.18 | 4.27 |
| Shareholders’ Equity Per Share | 2.80 | 0.86 | 1.74 | 2.18 | 4.27 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.04 | -0.17 | 0.00 | 0.00 | -0.00 |
| Revenue Per Share | 1.92 | 0.51 | 0.77 | 0.29 | 0.96 |
| Net Income Per Share | 1.50 | -2.28 | -1.30 | -0.78 | -0.29 |
| Tax Burden | 0.96 | 1.17 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.92 | 1.09 | 1.03 | 1.01 | 1.05 |
| Research & Development to Revenue | 0.12 | 1.78 | 1.45 | 1.95 | 0.35 |
| SG&A to Revenue | 0.73 | 2.32 | 0.00 | 1.51 | 0.30 |
| Stock-Based Compensation to Revenue | 0.12 | 0.63 | 0.22 | 0.42 | 0.09 |
| Income Quality | -0.02 | 0.66 | 0.73 | 0.45 | -1.22 |
Currency in USD